Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 3/20 | 0.39 |
| ▸ | THRA | P10827 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916651 | 0.82 | NR5A1 (0.43) | LTA4HHTR1BTHRATHRBHTR1D | |
| SCHEMBL23366501 | 0.75 | KDM4E (0.35) | HTR1BHTR1DLMNASIGMAR1 | |
| SCHEMBL24613003 | 0.71 | CYP1A2 (0.38) | LMNA | |
| SCHEMBL24613061 | 0.70 | TSHR (0.33) | TSHRLMNANPC1RAB9A | |
| SCHEMBL26720306 | 0.70 | SLC2A1 (0.33) | HTR1BTHRATHRBNR5A1TSHR | |
| SCHEMBL24613006 | 0.69 | ACACB (0.34) | LMNA | |
| SCHEMBL28063059 | 0.65 | HRH3 (0.57) | LTA4HNR5A1TSHRLMNARAB9A | |
| SCHEMBL10642885 | 0.64 | NR5A1 (0.62) | LTA4HTHRANR5A1TSHR | |
| SCHEMBL347683 | 0.64 | NR5A1 (0.62) | LTA4HTHRANR5A1TSHR | |
| SCHEMBL4945033 | 0.64 | NR5A1 (0.62) | LTA4HTHRANR5A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | SILICON VALLEY BANK | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | LTA4H 4009/4885HTR1B 4580/4885THRA 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.